Viewing Study NCT01339650

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:14 PM
Ignite Modification Date: 2026-01-29 @ 3:23 PM
Study NCT ID: NCT01339650
Status: COMPLETED
Last Update Posted: 2018-01-02
First Post: 2011-04-04
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: AbbVie (prior sponsor, Abbott)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fallopian Tube View
None Primary Peritoneal Cancer View
None Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Solid Tumor View
None BRCA 1 and BRCA 2 Mutations View
None Breast Cancer 1 View
None Breast Cancer 2 View
None High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancers View
None Solid Tumors View